Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
CMS opened a national coverage determination for Exact Sciences Cologuard, the first stool-based colorectal cancer screening test on the same day FDA approved the test. This is the first simultaneous approval/coverage determination under FDA and CMS’ joint parallel review program.
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
